Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00999167 · ClinicalTrials.gov registry record · Phase 2
A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy
A Phase 2 study of Cirrhosis and Hepatic Encephalopathy, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 189
- Enrollment target
- 20
- Study locations
NCT00999167 is a Phase 2 study of Cirrhosis and Hepatic Encephalopathy that has completed, run by Amgen. The registered enrollment target is 189 participants, below the 90,405-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT00999167, a Phase 2 study of Cirrhosis and Hepatic Encephalopathy, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 189 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2 study of HPN-100 in subjects with hepatic encephalopathy (HE) consisting of an open label safety lead-in (Part A), followed by randomized, double-blind, placebo-controlled treatment (Part B).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG HPN-100
Study Locations (20)
New York
- Concorde Medical Group PLLC - New York
- NYU Medical Center - New York
- Mount Sinai Medical Center - New York
- Columbia University Medical Center / Center for Liver Disease and Transplantation - New York
- University of Rochester Medical Center - Rochester
- New York Medical College / Westchester Medical Center - Valhalla
Florida
- University of Miami / Center for Liver Diseases - Miami
- Tampa General Hospital - Tampa
California
- Stanford University Medical Center, Division of Gastroenterology and Hepatology - Palo Alto
District of Columbia
- Georgetown University Hospital - Washington D.C.
Illinois
- The University of Chicago Medical Center - Chicago
Indiana
- Indiana University - Indianapolis
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 189 participants |
| Start Date | 2009-12 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00999167
The ClinicalTrials.gov registry entry for NCT00999167 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 189 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90,405-participant average among 53 other Cirrhosis trials with a reported enrollment target (100% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cirrhosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00999167 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, Florida, California.
Frequently Asked Questions
What is clinical trial NCT00999167 about?
NCT00999167 is a clinical study titled "A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy". This is a phase 2 study of HPN-100 in subjects with hepatic encephalopathy (HE) consisting of an open label safety lead-in (Part A), followed by randomized, double-blind, placebo-controlled treatment (Part B).
What is the current status of trial NCT00999167?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 189 participants. The study started on 2009-12. Estimated completion is 2012-04.
What conditions does trial NCT00999167 study?
This clinical trial studies the following conditions: Cirrhosis, Hepatic Encephalopathy.
What interventions are being tested in trial NCT00999167?
The interventions under investigation include: Placebo (DRUG), HPN-100 (DRUG).
Who is sponsoring clinical trial NCT00999167?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00999167 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Droxidopa to Increase Mean Arterial Pressure in Decompensated Cirrhosis Patients With Acute Kidney Injury
RECRUITING · Phase 2
-
A Prospective Study of Memantine in Patients With Cirrhosis and Liver Cancer
RECRUITING · Phase 2
-
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
RECRUITING · Phase 2
-
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
RECRUITING · Phase 2
-
Statin and Beta Blocker Use in Patients With Decompensated Cirrhosis
RECRUITING · Phase 2
-
Empagliflozin in Patients With Cirrhosis and Ascites
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.